Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RCKT 
Rocket Pharmaceuticals Inc (RCKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RCKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -2.64% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 619.52M USD | Price to earnings Ratio - | 1Y Target Price 41.6 |
Price to earnings Ratio - | 1Y Target Price 41.6 | ||
Volume (30-day avg) 1861074 | Beta 1.02 | 52 Weeks Range 5.79 - 26.98 | Updated Date 04/1/2025 |
52 Weeks Range 5.79 - 26.98 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.73 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.22% | Return on Equity (TTM) -54.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 272680576 | Price to Sales(TTM) - |
Enterprise Value 272680576 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.77 | Shares Outstanding 106630000 | Shares Floating 86243168 |
Shares Outstanding 106630000 | Shares Floating 86243168 | ||
Percent Insiders 3.02 | Percent Institutions 106.97 |
Analyst Ratings
Rating 4.65 | Target Price 43.13 | Buy 4 | Strong Buy 12 |
Buy 4 | Strong Buy 12 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rocket Pharmaceuticals Inc
Company Overview
History and Background
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. Founded in 2015, it has rapidly advanced its pipeline through clinical trials.
Core Business Areas
- Hematologic Malignancies: Developing gene therapies for Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease.
Leadership and Structure
Gaurav Shah is the CEO. The company has a structured management team overseeing research, development, and commercialization efforts.
Top Products and Market Share
Key Offerings
- RP-L102 (LAD-I): Gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). Currently in clinical trials. There is no market share yet. Competitors: Not explicitly available, gene therapy space is rapidly evolving.
- RP-L201 (Fanconi Anemia): Gene therapy for Fanconi Anemia (FA). Currently in clinical trials. There is no market share yet. Competitors: Not explicitly available, gene therapy space is rapidly evolving.
- RP-A501 (Danon Disease): Gene therapy for Danon Disease. Currently in clinical trials. There is no market share yet. Competitors: Not explicitly available, gene therapy space is rapidly evolving.
- RP-L301 (Pyruvate Kinase Deficiency): Gene therapy for Pyruvate Kinase Deficiency (PKD). Currently in clinical trials. There is no market share yet. Competitors: Not explicitly available, gene therapy space is rapidly evolving.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, driven by advancements in vector technology and increasing regulatory support for novel therapies. It is characterized by high risk and high reward.
Positioning
Rocket Pharmaceuticals is focused on rare disease gene therapies. Its competitive advantage lies in its specific disease targets and clinical trial progress.
Total Addressable Market (TAM)
TAM for gene therapies is expanding. Estimates vary widely. Rocket's positioning targets specific rare diseases, capturing a portion of the overall TAM. Precise TAM is unavailable.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Focus on rare and underserved diseases
- Experienced management team
- Proprietary technology platform
Weaknesses
- High development costs
- Regulatory hurdles and uncertainty
- Dependence on clinical trial success
- Cash burn rate
Opportunities
- Expanding gene therapy market
- Potential for regulatory approval and commercialization
- Partnerships with pharmaceutical companies
- Expansion into new disease areas
Threats
- Clinical trial failures
- Competition from other gene therapy companies
- Adverse safety events
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
- BEAM
Competitive Landscape
Rocket Pharmaceuticals competes with other gene therapy companies. Its success depends on the efficacy and safety of its therapies compared to competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth driven by pipeline advancement and clinical trial progress.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates are varied, and require real-time data pulling.
Recent Initiatives: Focus on advancing lead programs through clinical trials and securing partnerships.
Summary
Rocket Pharmaceuticals is a clinical-stage biotechnology company focused on gene therapies for rare diseases. Its success depends on successful clinical trials and regulatory approvals. The company faces high development costs and competition but has a strong pipeline and experienced management team. Future growth will be determined by pipeline advancement and market dynamics.
Similar Companies
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is unavailable without a proper source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rocket Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cranbury, NJ, United States | ||
IPO Launch date 2015-02-18 | CEO & Director Dr. Gaurav D. Shah M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 299 | Website https://www.rocketpharma.com |
Full time employees 299 | Website https://www.rocketpharma.com | ||
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.